Spontaneous virologic suppression in HIV controllers is independent of delayed-type hypersensitivity test responsiveness

AIDS Research and Therapy

Volumn 9, Issue , 2012, Pages

  Okulicz, Jason F ^a,b   Grandits, Greg A ^c   Dolan, Matthew J ^d   Marconi, Vincent C ^e   Wortmann, Glenn ^a,f   Landrum, Michael L ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Delayed type hypersensitivity test; Elite controllers; HAART; HIV; HIV controllers

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DELAYED TYPE HYPERSENSITIVITY TEST; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN TEST; SPONTANEOUS VIROLOGIC SUPPRESSION; VIRUS LOAD;

EID: 84859121866     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-9-10     Document Type: Article

References (13)

1. Dolan MJ, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995, 172(1):79-87. 10.1093/infdis/172.1.79, 7797948.
2. Blatt SP, et al. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993, 119(3):177-184.
3. Carr A, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 2000, 14(9):1171-1180. 10.1097/00002030-200006160-00014, 10894281.
4. Anastos K, et al. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004, 35(4):383-392. 10.1097/00126334-200404010-00008, 15097155.
5. Dolan MJ, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007, 8(12):1324-1336. 10.1038/ni1521, 17952079.
6. Okulicz JF, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009, 200(11):1714-1723. 10.1086/646609, 19852669.
7. Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS 2011, 6(3):163-168. 10.1097/COH.0b013e328344f35e, 21502920.
8. Marconi VC, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther 2010, 7:14. 2894737, 20507622.
9. Birx DL, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr 1993, 6(11):1248-1257.
10. Horster S, et al. Influence of antiretroviral therapy on immunogenicity of simultaneous vaccinations against influenza, pneumococcal disease and hepatitis A and B in human immunodeficiency virus positive individuals. J Infect 2010, 61(6):484-491. 10.1016/j.jinf.2010.09.030, 20875454.
11. Hunt PW, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008, 197(1):126-133. 10.1086/524143, 18171295.
12. Valdez H, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000, 14(1):11-21. 10.1097/00002030-200001070-00002, 10714563.
13. Wendland T, et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS 1999, 13(14):1857-1862. 10.1097/00002030-199910010-00007, 10513643.